GSC
MRTX

Ground Swell Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ground Swell Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$5K Buy
+273
New +$5.09K 0.01% 1490

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ground Swell Capital's MRTX Position: Q3 2014 in Review

Ground Swell Capital opened a new position in Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2014: 273 shares worth $5K. The stake represents 0.01% of the portfolio and ranks #1490 among its holdings.

43 funds tracked by Wall St. Rank hold MRTX as of Q3 2014.

  • Ground Swell Capital held 273 shares of Mirati Therapeutics, Inc. Common Stock worth $5K as of Q3 2014.
  • Mirati Therapeutics, Inc. Common Stock was a new Ground Swell Capital position in Q3 2014.
  • Mirati Therapeutics, Inc. Common Stock made up 0.01% of Ground Swell Capital's portfolio in Q3 2014, its #1490 holding.
  • 43 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.